irinotecan has been researched along with er-086526 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA | 1 |
| Barisella, M; Brich, S; Casanova, M; Collini, P; Dagrada, GP; Doldi, V; Ferrari, A; Fiore, M; Frezza, AM; Gasparini, P; Gronchi, A; Pasquali, S; Percio, S; Stacchiotti, S; Tortoreto, M; Zaffaroni, N; Zuco, V | 1 |
2 other study(ies) available for irinotecan and er-086526
| Article | Year |
|---|---|
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Ketones; Kidney Neoplasms; Mice; Mice, SCID; Prognosis; Rhabdomyosarcoma; Tumor Cells, Cultured; Vincristine; Wilms Tumor; Xenograft Model Antitumor Assays | 2020 |
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
Topics: Antineoplastic Agents; Desmoplastic Small Round Cell Tumor; Heterografts; Humans; Irinotecan; Trabectedin | 2023 |